August 2025 2025 FIRST HALF RESULTS REVIEW O U R B U S I N E S S 2025 First Half Results Review ~ Stock Code: 0270 F I N A N C I A L H I G H L I G H T S 1 The unaudited consolidated profit attributable to owners of the Company for 1H25 increased by 11.2% to HK$2,682 million and interim dividend per share increased by 11.2% to HK$26.66 cents. 2 The net finance costs from continuing operations was decreased by HK$201 million to HK$188 million and net loss arising from fair value adjustments for investment pro ...

BOARD AND MANAGEMENT INTERIM RESULTS PRESENTATION AUGUST 27, 2025 DISCLAIMER This presentation contains forward-looking statements that involve risks and uncertainties. These statements are generally indicated by the use of forward-looking terminology such as "believe", "expect", "anticipate", "estimate", "plan", "project", "target", "may", "will" or other similar words that express an indication of actions or results of actions that may or are expected to occur in the future. You should not place undue rel ...

Business Highlights - Akeso's commercial sales revenue in 2025H1 reached RMB 1.402 billion, a 49% year-on-year increase[16, 24] - The company has 13 Phase III/registrational trials of ivonescimab covering lung cancer and expanding to cold tumors[13] - The company has 10 phase III clinical studies of cadonilimab across lung cancer, gastric cancer, liver cancer and cervical cancer[13] - Penpulimab receives FDA approval in the United States[14] Pipeline Development - Three blockbuster new drug candidates entered clinical stage[19] - Six Phase III clinical trials reached the primary endpoint[20] - Ivonescimab's first global Phase III trial received positive results[84] - Manfidokimab (IL-4Rα) Reached Endpoints in the Registrational Phase III Trial for Atopic Dermatitis[116] Financial Performance - 1H 2025 Revenue reached RMB 1.412 billion, a 33.7% growth from 1H in 2024[16] - The company has cash and short-term financial assets of approximately RMB 7.14 billion[16] - Sales and Marketing expense as a percentage of sales decreased from 55% in 2024H1 to 48% in 2025 H1[136, 140]

AGENDA 01. HIGHLIGHTS 04.ESG 02. FINANCIAL REVIEW 03.BUSINESS REVIEW 05. LAND BANK 06. OUTLOOK 07.APPENDIX 三亚海棠湾悦府 西安万象城 Xi'an Mixc P A R T PART ONE Results Highlights Strengthening Momentum of the Second Growth Curve for Stable Performance and Returns Revenue +19.9% YoY Recurring Income +2.5% YoY RMB 94.9bn RMB 20.6bn Weighted Average Funding Cost 2.79% -32bps from FY24 Attributable Net Profit +16.2% YoY Recurring Core Net Profit RMB 11.9 +9.6% YoY bn RMB 6.0bn Net Gearing Ratio 39.2% Core Net Profit -6.6% ...

Financial Performance - The company's revenue reached RMB 131867 million, a 25% year-over-year increase[11] - Gross profit increased to RMB 21510 million, representing a 28% increase[11] - Net profit attributable to shareholders was RMB 2077 million, a decrease of 203%[11] - Operating cash flow significantly improved, reaching RMB 1531 million, a 2501% increase compared to the previous year[11] Business Segments - Pharmaceutical manufacturing business revenue was RMB 2481 billion, up 43% year-over-year, while segment gross profit margin decreased by 08 percentage points to 593%[19, 20] - Commercial business revenue increased by 23% to RMB 108330 million[62] - The medical device business achieved revenue of RMB 18 billion, an 8% year-over-year increase[70] Strategic Initiatives - The company completed the acquisitions of Nigale and Tasly to expand into the medical device sector and solidify its position in the TCM industry[22, 24] - The company is committed to innovative R&D, with 476 total projects under research and development, including 178 new drugs[36] - The company is strengthening international expansion, with overseas API revenue reaching RMB 360 million in the first half of the year[53, 58]

Financial Performance - Clean Energy revenue significantly increased by 222% YoY[9], reaching RMB 9626 million[9] - Basic Earnings Per Share Increased to RMB 0278 per share[12] - Net Asset Value (NAV) per Share increased to RMB 6540 per share[14] - Annualised ROE Increased by 1pp to 97% YoY[15] - Overall Cash Conversion Cycle (CCC) was 25 days[18], optimised by 11 days YoY[18] Segment Results and Orders - Clean energy reportable segment profit increased significantly by 295% YoY[31], reaching RMB 560 million[31] - Newly signed orders for clean energy totaled RMB 897 billion[40], with offshore clean energy accounting for RMB 324 billion[40] - Backlog orders of clean energy stood at RMB 2520 billion[43], up 10% YoY[43] - Newly signed orders for liquid food reached RMB 690 million[40], a 62% QoQ increase from Q1 to Q2 in 2Q25[40] Business Highlights and Outlook - China's LNG imports declined by 206% YoY[59] to 3011 million tons[59] - The global tank container fleet reached 882023 units[147], representing an increase of 396% compared with 2024[147] - CLPT completed a new round of private placement in July 2025[154], raising RMB 110 million[154] and adding 19079434 new shares[154]

2025 Interim Results Presentation August 2025 China Everbright Environment Group Limited Forward-looking Statement This presentation may contain forward-looking statements. Any such forward-looking statements are based on a number of assumptions about the operations of China Everbright Environment (Group) Limited ("Everbright Environment" or the "Company", together with its subsidiaries, collectively the "Group") and factors beyond the Company's control and are subject to significant risks and uncertainties ...

Global Wind Power Market - Global new wind power installations in 2024 reached 117.0 GW, with 109.0 GW from onshore wind and 8.0 GW from offshore wind[7] - APAC accounted for 75% of total global installations in 2024, while Europe represented 14% and North America contributed 5%[7] - The levelized cost of global onshore wind power declined by 70% from 0.113 USD/kWh in 2010 to 0.034 USD/kWh in 2024[7] - The levelized cost of global offshore wind power decreased by 62% from 0.208 USD/kWh in 2010 to 0.079 USD/kWh in 2024[7] China Wind Power Development - China's new grid-connection capacity in the first half of 2025 was 51.4 GW, a 98.9% year-over-year increase, including 48.9 GW of onshore wind and 2.5 GW of offshore wind[14] - As of June 2025, China's cumulative grid-connected wind power capacity totaled 572.6 GW, accounting for 15.7% of China's power mix[14] - Wind power production in China increased 15.6% year-over-year to approximately 588.0 billion kWh in the first half of 2025, representing a penetration rate of 12.1%[14] - China's domestic public tender market totaled 71.9 GW in the first half of 2025, representing an 8.8% year-over-year increase[21] Goldwind's Performance - Goldwind's external sale capacity totaled 10,641 MW in the first half of 2025, an increase of 106.6% year-over-year, with 81.5% (8,672 MW) from WTG 6MW and above[29] - As of June 30, 2025, Goldwind's total order backlog was 54.8 GW, with external order backlog totaling 51.8 GW[35] - As of June 30, 2025, Goldwind's cumulative installation in overseas market is 10,025.53 MW[39] - Goldwind's revenue for the first half of 2025 totaled RMB 28,537 million, with a comprehensive profit margin of 15.35% and a net profit attributable to owners of the company of RMB 1,488 million[61]

West China Cement 1 Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of West China Cement Limited (the "Issuer" together with its subsidiaries, the "Group") for use in presentations by the Issuer at investor meetings for information purposes only and does not constitute a recommendation, invitation or offer to acquire, pur ...

Financial Performance - Henlius achieved a revenue of RMB 2.82 billion in 2025 H1, representing a 2.7% year-over-year growth[5, 207, 212] - Product sales reached RMB 2.56 billion in 2025 H1, a 3.1% year-over-year increase[6, 207, 212] - The company's net profit was RMB 386 million, with a net profit margin of 13.8%[5, 6] - Net operating cash inflow reached RMB 770 million, showing a 207% year-over-year growth[6] Business Development & Out-licensing - BD contract cash inflow exceeded RMB 1 billion in 2025 H1, a 280% year-over-year growth[6] - Out-licensing deals include HLX13 (Ipilimumab) to Sandoz for up to USD 300 million, HLX15 (daratumumab) to Dr Reddy's for up to USD 131.6 million, and HANSIZHUANG (serplulimab) to Lotus in South Korea for up to USD 112 million[6, 48] - Recent major out-licensing products contributed cash inflow of approximately RMB 670 million in 1H25[47] Key Products Performance - HANSIZHUANG sales reached RMB 0.6 billion in 2025 H1[6] - HANQUYOU global revenue in 1H2025 was RMB 1.44 billion[146] - HANBEITAI revenue in 1H2025 was RMB 116 million[176] - HANNAIJIA revenue in 1H2025 was RMB 97 million[158] - HANLIKANG revenue in 1H2025 was RMB 274 million[186] - HANDAYUAN revenue in 1H2025 was RMB 27 million[186]